Fulgent Genetics, Inc. (NASDAQ:FLGT – Get Free Report) COO Jian Xie sold 715 shares of the business’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $22.83, for a total value of $16,323.45. Following the sale, the chief operating officer now owns 342,764 shares of the company’s stock, valued at approximately $7,825,302.12. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Fulgent Genetics Stock Performance
NASDAQ FLGT opened at $22.56 on Friday. Fulgent Genetics, Inc. has a one year low of $18.91 and a one year high of $33.97. The company’s 50 day moving average price is $22.32 and its 200 day moving average price is $21.97.
Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last issued its earnings results on Friday, August 2nd. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.45. Fulgent Genetics had a negative net margin of 56.22% and a negative return on equity of 2.75%. The business had revenue of $71.03 million for the quarter, compared to the consensus estimate of $69.07 million. During the same quarter last year, the firm posted ($0.33) EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities analysts anticipate that Fulgent Genetics, Inc. will post -1.46 earnings per share for the current year.
Institutional Inflows and Outflows
About Fulgent Genetics
Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.
See Also
- Five stocks we like better than Fulgent Genetics
- How to invest in marijuana stocks in 7 steps
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- The Basics of Support and Resistance
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- CD Calculator: Certificate of Deposit Calculator
- Why Dell Can Continue Winning in AI and Beyond
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.